Table 2.
Summary of bestoverall tumor response and time-to-treatment failure
| Measure | All Patients (N = 14) |
|---|---|
| Response, n (%) | |
| CR | 0 |
| CR | 0 |
| PR* | 1 (8) |
| SD | 6 (46) |
| CBR (PR + SD)** | 6 (46) |
| DCR (CR + PR + SD ≥ 6 months) | 0 |
| PD | 6 (46) |
| Not evaluated | 1 |
| TTF in weeks, median (range) | |
| All patients | 9 (2–48) |
| CBR patients | 13 (8–22) |
| Number of cycles, median (range) | |
| All patients | 2.5 (0–11) |
| CBR patients | 4 (2–7) |
Abbreviations: CBR, clinical benefit rate; CI, confidence interval; CR, complete
response; DCR, disease control rate; PD, progressive disease; PR, partial response;
SD, stable disease; TTF, time-to-treatment failure
* Unconfirmed PR (uPR) was observed in one patient with endometrial cancer
** Excludes uPR patient